Self-developed SNN Neuromorphic Chip, Acting as the 'Upstream Brain' of Medical Devices, 'Mien Technology' Raises Tens of Millions in Funding | 36Kr Exclusive
**Minneng Technology** has developed a proprietary Spiking Neural Network (SNN) neuromorphic chip designed specifically for medical devices, addressing the limitations of traditional MCU+ANN architectures in processing continuous physiological signals. The core innovation is an **event-driven architecture** that activates computation only when specific physiological events (e.g., ECG anomalies) occur, enabling ultra-low power consumption and 7x24-hour monitoring without overheating or battery dr
Analysis
TL;DR
- Minneng Technology has developed a proprietary Spiking Neural Network (SNN) neuromorphic chip designed specifically for medical devices, addressing the limitations of traditional MCU+ANN architectures in processing continuous physiological signals.
- The core innovation is an event-driven architecture that activates computation only when specific physiological events (e.g., ECG anomalies) occur, enabling ultra-low power consumption and 7x24-hour monitoring without overheating or battery drain.
- The company employs a "dual-track" commercialization strategy: rapid deployment of standardized modules for consumer health products to generate cash flow, while simultaneously building high-barrier clinical validation systems for serious neuro-medical applications like chronic pain management and sleep regulation.
- They offer a five-tier delivery model ranging from pure hardware supply (L1) to full regulatory support and small-batch manufacturing assistance (L5), catering to both established medical device giants and clinician-founded startups lacking hardware expertise.
Why It Matters
This article highlights a critical shift in AI hardware design: moving away from general-purpose deep learning models toward specialized, bio-inspired architectures optimized for real-time, low-power signal processing in safety-critical environments. For AI practitioners, it demonstrates the value of co-designing algorithms with hardware constraints—specifically how event-based computing can solve the latency and energy bottlenecks plaguing wearable health tech. For the industry, it underscores the growing importance of "upstream" foundational platforms rather than just end-user applications, suggesting future winners may be those who control the sensor-to-signal pipeline itself.
Technical Details
- Neuromorphic Core: Uses analog-digital hybrid SNNs mimicking biological neuron sparsity and asynchronous firing patterns, contrasting with conventional artificial neural networks that process data continuously regardless of relevance.
- Physiological Pulse Encoding Mechanism: Implements custom encoding schemes tailored to EEG, ECG, EMG waveforms; triggers computational wakefulness exclusively upon detecting feature mutations in biosignals rather than fixed sampling intervals.
- Three-Layer Hardware Stack:
- Multi-modal sensory array supporting dry/half-dry electrodes for capturing weak bioelectric/optical signals;
- Event-driven neuromorphic processor performing sparse filtering and state assessment;
- Programmable control unit enforcing multi-layered hardware-level safety rules before any intervention output.
- End-to-End Integration: Proprietary toolchains, standardized test datasets, and compliance frameworks eliminate third-party component dependencies, reducing integration friction for OEM partners.
Industry Insight
The rise of personalized medicine and aging populations will increasingly demand long-term, unobtrusive home-based monitoring solutions—making energy-efficient edge AI not optional but essential. Companies investing now in domain-specific neuromorphic infrastructure (like Minneng’s closed-loop sensing-computation-control stack) are positioning themselves as indispensable suppliers to legacy medtech firms struggling to modernize their product lines. Meanwhile, clinicians-turned-founders should prioritize partnerships over vertical integration if they lack semiconductor R&D capacity; tiered service models like L3–L5 lower entry barriers significantly. Finally, regulatory approval timelines remain a major hurdle—early collaboration with hospitals on clinical trials (as noted in their “serious medicine” track) could accelerate market access by validating both efficacy and safety concurrently with engineering development.
Disclaimer: The above content is generated by AI and is for reference only.